Identifying Cut-off Values, Effects of AD Co-pathology, Sex Differences, and Temporal Changes of 123I-FP-CIT SPECT in Autopsy-proven LBD
Objective: We analyzed autopsy-proven Lewy body disease (LBD) and/or Alzheimer’s disease (AD) dementia patients with 123I-FP-CIT SPECT to investigate previously unclarified detailed aspects of 123I-FP-CIT…Preoperative Occipital Hypoperfusion Predicts Cognitive Decline after Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Objective: This study aimed to identify the preoperative cerebral blood flow (CBF) regions associated with frontal lobe dysfunction after subthalamic nucleus deep brain stimulation (STN…Brain perfusion patterns associated with motor symptoms in multiple system atrophy
Objective: There is a need for objective methods to assess disease progression in multiple system atrophy (MSA). This study aimed to identify brain perfusion patterns…Cerebrospinal fluid DOPA decarboxylase levels as a marker of disease severity in Parkinson’s Disease
Objective: To assess the correlation of CSF DDC levels to DaT-SPECT SBR in PD and iRBD. Background: Raised cerebrospinal fluid (CSF) proteomic biomarker, DOPA decarboxylase…Results From a Dose-Blinded, Phase II Extension Study Evaluating Long-Term Efficacy, Safety and Tolerability of Minzasolmin in Participants With Parkinson’s Disease
Objective: ORCHESTRA XT (PD0055; NCT05543252) was a Phase II, dose-blinded extension of the ORCHESTRA Phase II, proof-of-concept study (NCT04658186). ORCHESTRA XT assessed the pharmacodynamic effects of…Identifying subjects at high risk for prodromal Parkinson’s Disease using dopamine transporter imaging deficit in a step-wise recruitment strategy: Data of Healthy Brain Ageing (HeBA)
Objective: To optimize screening for subjects with dopamine transporter (DaT) imaging deficit being at high risk for prodromal Parkinson's disease (PD). Background: Efficient screening methods…A Prospective, Observational Study to Identify Biomarkers in Parkinsonian Syndromes (proATYP).
Objective: This is a prospective observational study to identify biomarkers in parkinsonian syndromes. Background: Parkinson’s disease (PD) and atypical parkinsonian syndromes namely progressive supranuclear palsy…A multi-center, randomized, controlled study of the add-on effect of selegiline or zonisamide to L-dopa/DCI therapy in Parkinson’s disease (DATSZ-PD study)
Objective: To investigate the efficacy and safety for neuroprotection and disease modifying effect in selegiline(SL) or zonisamide(ZN) by using UPDRS, PDQ-39 and DAT -SPECT in…Dopamine Transporter Imaging as a Predictor of Functional Outcomes in Parkinson’s Disease
Objective: To evaluate the prognostic value of dopamine transporter (DAT) imaging in predicting future disability, as well as motor and non-motor burden, in Parkinson’s disease…Semi-quantitative Evaluation of Midbrain Accumulation in 123I-FP-CIT SPECT in Parkinson’s disease and Parkinsonian Syndromes
Objective: To establish a method for evaluating midbrain accumulation of 123I-FP-CIT SPECT and assess its ability to differentiate between Parkinson’s disease (PD) and Parkinsonian syndromes…
- 1
- 2
- 3
- …
- 15
- Next Page »